Detalles de la búsqueda
1.
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Am J Hematol
; 98(5): 739-749, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36810799
2.
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018).
Am J Hematol
; 97(9): 1150-1158, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35713565
3.
Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel.
Eur J Haematol
; 107(1): 48-53, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33655560
4.
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Blood
; 132(21): 2240-2248, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262659
5.
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET.
Haematologica
; 108(6): 1697-1701, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36546451
6.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
Blood
; 126(3): 328-35, 2015 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25921059
7.
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Blood
; 121(20): 4137-41, 2013 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-23493782
8.
Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.
J Cell Sci
; 125(Pt 18): 4253-63, 2012 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22718346
9.
Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.
Am J Hematol
; 94(9): E245-E247, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31211433
10.
Targets and treatments in primary CNS lymphoma.
Leuk Lymphoma
; : 1-13, 2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38659230
11.
Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
Br J Haematol
; 183(4): 674-678, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29076134
12.
Successful Anatomy Adapted Therapeutic Management and Genetic Profiling of Primary Pituitary Diffuse Large B-Cell Lymphoma.
Blood Lymphat Cancer
; 13: 25-32, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37533879
13.
90Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases.
Blood Lymphat Cancer
; 13: 59-65, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37810176
14.
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Front Immunol
; 14: 1239082, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954584
15.
Successful CNS-Centric Therapeutic Management and Genomic Profiling of Primary Cranial Vault Diffuse Large B-Cell Lymphoma.
J Blood Med
; 14: 49-55, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36712581
16.
Multiply Relapsed Secondary CNS Non-Germinal Center Diffuse Large B-Cell Lymphoma Successfully Treated with CNS-Centric Therapy.
J Blood Med
; 14: 455-461, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37605778
17.
Poly-lymphomatous Syndrome With Concurrent or Sequential Hodgkin and Non-Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk
; 23(2): 138-144, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36509650
18.
Hyperviscosity Syndrome Induced Bilateral Visual and Auditory Impairment in Therapy Resistant Waldenström Macroglobulinemia with MYD88 and CXCR4 Mutations.
J Blood Med
; 14: 639-648, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38116327
19.
Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Clin Lymphoma Myeloma Leuk
; 23(4): 259-265, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36775698
20.
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases.
Clin Cancer Res
; 29(9): 1751-1762, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36749885